Cambium Bio (ASX:CMB) Short-Term Debt: A$0.00 Mil (As of Dec. 2025)


ASX:CMB Cambium Bio Ltd ASX:CMB
35 GF Score
Price A$0.44
! 4 Warning Signs
View Full Analysis

What is Cambium Bio Short-Term Debt?

Cambium Bio ASX:CMB -1.14% 35 Short-Term Debt is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:CMB with a GF Score™ of 35/100. The stock has 4 warning signs investors should review.

Cambium Bio's Short-Term Debt for the quarter that ended in Dec. 2025 was A$0.00 Mil.

Cambium Bio's quarterly Short-Term Debt increased from Dec. 2024 (A$0.00 Mil) to Jun. 2025 (A$0.32 Mil) but then declined from Jun. 2025 (A$0.32 Mil) to Dec. 2025 (A$0.00 Mil).

Cambium Bio's annual Short-Term Debt declined from Jun. 2023 (A$1.95 Mil) to Jun. 2024 (A$0.00 Mil) but then increased from Jun. 2024 (A$0.00 Mil) to Jun. 2025 (A$0.32 Mil).

Cambium Bio Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Cambium Bio Short-Term Debt Related Terms

Cambium Bio Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Cambium Bio's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cambium Bio Short-Term Debt Chart

Cambium Bio Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 1.00 1.95 0.00 0.32

Cambium Bio Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.32 0.00
ASX:CMB
35GF Score
Cambium Bio Ltd ASX:CMB
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of A$0.00 Mil mean?
Cambium Bio (ASX:CMB) has a Short-Term Debt of A$0.00 Mil as of Dec. 2025.
Is Cambium Bio's Short-Term Debt too high?
Cambium Bio's current Short-Term Debt is A$0.00 Mil. Overall, Cambium Bio has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Cambium Bio's Short-Term Debt compare to VRTX and REGN?
Cambium Bio's Short-Term Debt of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Cambium Bio's current Short-Term Debt is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cambium Bio stock overvalued right now?
Cambium Bio (ASX:CMB) has a current Short-Term Debt of A$0.00 Mil. The current Short-Term Debt is A$0.00 Mil. Cambium Bio's overall GF Score™ is 35/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Cambium Bio (ASX:CMB), the current Short-Term Debt is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cambium Bio Business Description

Address Unit 2.06, 31 Lexington Drive, Bella Vista, NSW, AUS, 2153
Cambium Bio Ltd is a clinical-stage regenerative medicine company in Australia. It focuses on the development of biologics for ophthalmology and tissue repair applications. Its technology platform is based on human platelet lysate, which is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The company's product candidate, Elate Ocular, is being developed to address unmet medical needs in the treatment of dry eye disease. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.
35GF Score

Get the complete analysis for ASX:CMB

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.44
Price